Solar stocks surge after Treasury tightens clean energy tax credit rules
NEW YORK - Citius Oncology, Inc. (NASDAQ:CTOR) announced Thursday the closing of its public offering that raised approximately $9 million in gross proceeds before deducting placement agent fees and other expenses. The announcement comes as the stock trades at $1.60, having experienced significant volatility with a -52% return over the past week, according to InvestingPro data.
The company, a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), offered 6,818,182 shares of common stock and warrants at a public offering price of $1.32 per share. The warrants have an exercise price matching the offering price and will be valid for five years.
Maxim Group LLC served as the sole placement agent for the offering.
Citius Oncology plans to use the proceeds primarily to support the commercialization of LYMPHIR, its FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have had at least one prior systemic therapy. The funds will also cover milestone and royalty payments under existing license agreements, as well as working capital and general corporate purposes.
The offering was conducted under a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on July 16, 2025.
LYMPHIR received FDA approval in August 2024. According to information provided in the company’s press release statement, management estimates the initial market for the treatment exceeds $400 million.
Citius Pharmaceuticals owns 92% of Citius Oncology, which focuses on developing and commercializing targeted oncology therapies.
In other recent news, Citius Oncology has made significant strides in expanding the distribution network for its FDA-approved immunotherapy, LYMPHIR. The company has entered into a distribution services agreement with Cencora, formerly AmerisourceBergen, to serve as a wholesale distributor, enhancing the reach of LYMPHIR across the United States. Additionally, a strategic partnership with Cardinal Health has been established to facilitate the U.S. commercial launch of LYMPHIR, further solidifying its distribution strategy. Meanwhile, Citius Pharmaceuticals, the parent company of Citius Oncology, has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the exchange.
Citius Pharmaceuticals has also announced a registered direct offering expected to generate $6 million in gross proceeds, with potential additional funds from short-term warrants. The proceeds are intended to support the commercial launch of LYMPHIR and other corporate initiatives. The company is actively preparing for LYMPHIR’s commercial launch in the second half of 2025, having completed commercial-scale manufacturing and established distribution agreements for nationwide delivery.
Citius Oncology is also engaged in strategic partnership discussions to expand LYMPHIR’s market reach and has secured its inclusion in the National Comprehensive Cancer Network Clinical Practice Guidelines. These developments highlight the company’s commitment to ensuring broad access to its innovative treatment for cutaneous T-cell lymphoma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.